DexCom (DXCM) 10-K Summary — Year Ended Dec 31, 2023

DexCom reported annual results with revenue growth and positive profitability. The company's liquidity is supported by cash, marketable securities, operations, and debt, with capital allocation focused on R&D, sales, marketing, and acquisitions.

Key takeaway

Year ended Dec 31, 2023 · FY2025 10-K

Financial snapshot

Selected annual figures reported with the filing, shown separately from the narrative summary.

Annual revenue

$3.6B

Revenue reported for the fiscal year.

Operating income

$597.7M

Income from operations reported for the year.

Net income

$541.5M

Net income reported for the year.

Operating cash flow

$748.5M

Cash generated by operating activities.

Annual revenue trend

Reported annual revenue and its change from the preceding fiscal year.

Period ended	Revenue	Year-over-year change
Dec 31, 2021	$2.4B	n/a
Dec 31, 2022	$2.9B	+18.8%
Dec 31, 2023	$3.6B	+24.5%

Business overview

The company engages in research and development, selling and marketing, capital expenditures, and acquisitions. It sells approved products and develops future products, as described in the liquidity section of the filing.

Financial performance

Revenue increased compared to the prior year, and the company reported positive operating income and net income. Operating cash flow was also positive.

Material risks

The filing references risk factors but does not provide specific risk descriptions in the supplied context.

Liquidity and capital

The company uses cash, marketable securities, operating cash flow, and debt as liquidity sources. Cash is allocated to research, marketing, capital spending, acquisitions, and debt service. Future capital needs depend on international expansion and product revenue.

What to watch

Monitor the company's international expansion and revenue from approved and future products.